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Abstract
Background: PUFAs are potent inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, an
enzyme catalyzing the conversion of HMGCoA to mevalonate, the rate limiting step in cholesterol biosynthesis.
Statins represent a class of drugs that are widely used to treat hypercholesterolemia for their ability to inhibit
cholesterol biosynthesis and to up-regulate the synthesis of Low Density Lipoprotein (LDL) receptors in the liver.
PUFAs mediate many, if not all, actions of statins and this could be one mechanism by which they lower
cholesterol levels. The purpose of this study was to investigate whether combined treatment with
Eicosapentaenoic acid (EPA) and lovastatin enhanced the regulatory effect on gene expression of HMGCoA
reductase and LDL receptor in HepG2 cell line.
Results: The combined treatment with EPA and lovastatin enhanced the regulatory effect on gene expression of
HMGCoA reductase and LDL receptor in HepG2 cell line. Moreover, we detected a synergistic effect on the
inhibition of cancer cell proliferation obtained by combination of EPA and Lovastatin.
Conclusions: The use of EPA, in combination with low doses of Lovastatin may have potential value in treatment
of neoplastic diseases.
Introduction
Long-chain polyunsaturated fatty acids (PUFAs), named
for the position of their terminal double bond, the n-6
and n-3 long-chain PUFAs, are part of the phospholipid
structure of all membranes and play additional roles as
signaling molecules and modulators of gene expression
[1-3]. Long-chain PUFAs may be directly consumed in
the diet or synthesized from their essential fatty acid
precursors, linoleic acid (LA) and a-linolenic acid
(LNA) [4].
Clinical studies from cardiovascular medicine, psychia-
try and other disciplines have demonstrated correlations
between low n-3 PUFA levels and increased disease risk
[5,6] and have shown that increasing n-3 levels by diet
or supplementation may confer a variety of health
benefits [1,7,8]. A major effect of n-3 PUFA is to lower
plasma triacylglycerols and lipoprotrein concentrations,
in normal as well as hypertriglyceridaemic subjects [9].
PUFAs are potent inhibitors of 3-hydroxy-3-methyl-
glutaryl coenzyme A (HMG-CoA) reductase, an enzyme
catalyzing the conversion of HMGCoA to mevalonate,
the rate limiting step in cholesterol biosynthesis. PUFAs
mediate many, if not all, actions of statins [10] and this
could be one mechanism by which they lower choles-
terol levels.
Statins represent a class of drugs that are widely used
to treat hypercholesterolemia for their ability to inhibit
cholesterol biosynthesis and to up-regulate the synthesis
of Low Density Lipoprotein (LDL) receptors in the liver
[11].
Statins having biochemical effects on cholesterol
synthesis, are considered as potential anti-tumor agents
[12], inhibiting tumor cell growth by restricting either
cholesterol availability or cholesterol synthesis [12,13].
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greatly limited by their high-dose toxicity that is charac-
terized by severe myopaty [14].
An important feature of malignant transformation is
the loss of the cholesterol feedback inhibition mechan-
ism that regulates cholesterol synthesis. The main cho-
lesterol feedback defect in malignant cells has been
located at the HMGCoA reductase step.
Cancer cells seem to require an increased concentra-
tion of cholesterol and cholesterol precursors and this
requirement may be fulfilled by increased HMGCoA
reductase activity.
In our previous study, HMGCoA reductase activity
was found to be enhanced in human colorectal cancer
that did not express LDL receptors [15], indicating that
LDL receptors absence, which deprives colonic neoplas-
tic cells of exogenous sterols, is overcome by an increase
in endogenous cholesterol synthesis.
Several studies [15-17] have demonstrated that the
absence of LDL receptor induces neoplastic cells to
depend on endogenous cholesterol synthesis for their
proliferation, resulting in an increase of HMGCoA
reductase activity inside the cells. Several studies showed
that HMGCoA inhibitor blockade of mevalonate synth-
esis induced cell cycle arrest in vitro [18-20] and inhib-
ited tumor growth in vivo [21].
Previously, we have demonstrated an anti-proliferative
effect of simvastatin in two human colon cancer cell
lines [16]. Simvastatin inhibited cell proliferation at
pharmacological doses in DLD-1 and Caco2 cell lines.
The growth inhibition by simvastatin observed in DLD-
1 cells was mediated by a proapoptotic effect, whereas
in Caco2 cells the anti-proliferative effect takes place
regardless of apoptosis.
In the present study we investigated in vitro whether
combined treatment with Eicosapentaenoic acid (EPA),
belonging to omega-3 family, and lovastatin enhanced
t h er e g u l a t o r ye f f e c to ng e n ee x p r e s s i o no fH M G C o A
reductase and LDL receptor in HepG2 cell line.
Materials and methods
Cell culture conditions
HepG2, a cell line derived from human liver tissue with
a well differentiated hepatocellular carcinoma, were
obtained from the ICLC (IST, Genoa, Italy).
Cells were routinely cultured in DMEM (Dulbecco’s
modified Eagle’s medium) supplemented with 10% FBS
(fetal bovine serum), 100 U/ml penicillin, 100 μg/ml
streptomycin, in monolayer culture, and incubated at
37°C in a humidified atmosphere containing 5% CO2 in
air. At confluence, the grown cells were harvested by
means of trypsinization and serially subcultured with a
1:4 split ratio. All cell culture components were pur-
chased from Sigma-Aldrich (Milan, Italy).
Lovastatin and EPA treatment
To elucidate the effect of Lovastatin and EPA on HMG-
CoA reductase, LDL receptor gene expression and cell
proliferation, HepG2 cells were plated at a density of
3×1 0
5 cells/5 ml of DMEM containing 10% FBS in
60-mm tissue culture dishes (Corning Costar Co., USA).
Separate plates were seeded for each assay and when
the cells were approximately 60% confluent were
exposed to the treatment.
To examine the response to EPA, HepG2 cells were
treated for 48 h with culture medium supplemented
with various concentrations of EPA (1, 10, 25, 50 and
100 μM). Each experiment included a control without
EPA and a control with the same amount of DMEM
-BSA used for dissolving the fatty acid.
To evaluate Lovastatin effect on HepG2 cells, the drug
dissolved in 0,1 N NaOH was added to the culture med-
ium at increasing concentrations (1, 10, 25, 50 and 100
μM) and incubated for 48 hours. Each experiment
included an untreated control and a control that
received the same amount of NaOH used for adding
Lovastatin.
For the experiment testing the effect of combined
treatment of Lovastatin and EPA on subconfluent
HepG2 cells two sets of experiments were prepared. In
the first set, HepG2 cells were incubated with 50 μMo f
EPA and increasing concentrations of Lovastatin (1,10,
25, 50 and 100 μM). The second set of experiments
were performed by incubating HepG2 with Lovastatin at
the concentration of 50 μM with increasing concentra-
tions of EPA (1,10, 25, 50 and 100 μM) (data not
shown). In these experimental conditions, HepG2 cells
were allowed to growth for 48 h. Each experiment
included an untreated control and a control with the
equivalent concentration of solvent used for adding
Lovastatin and EPA.
Triplicate culture were set up for each compound
concentration and for control, and each experiment was
repeated 4 times. Cell viability, determined using the
trypan blue exclusion test, always exceeded 90%.
LDL receptor and HMG-CoA reductase gene expression
Analysis of gene expression was performed in HepG2
cells treated with 1, 10, 25, 50 and 100 μM of EPA and
Lovastatin alone and with both compounds at estab-
lished concentrations for 48 hours.
Cells were washed twice in phosphate buffered saline
(PBS) and then trypsinized and centrifuged at low
speed. The cell pellets were resuspended in 0.3 ml pure
distilled water and used for RNA extraction.
Total cell RNA was isolated with TRI-Reagent (Mol.
Res. Centre Inc. Cincinnati, USA), following the manu-
facturer’s instruction. Total cell RNA was extracted
using Tri-Reagent (Mol. Res. Center Inc., Cincinnati,
Notarnicola et al. Lipids in Health and Disease 2010, 9:135
http://www.lipidworld.com/content/9/1/135
Page 2 of 8Ohio, USA), following the manifacture’si n s t r u c t i o n .
About 2 μg total cell RNA, extracted from both the con-
trol and treated cells, was used for cDNA synthesis.
Reverse transcription (RT) was carried out in 20 μlo f
the final volume at 41°C for 60 min, using 30 pmol anti-
sense primer (Table 1) for analyses of the HMGCoA
reductase, LDL receptor and b-actin gene. The b-actin
gene was utilized as an internal control and was chosen
as a reference gene because it is a housekeeping gene.
Real-time PCRs were performed in 25 μlf i n a lv o l u m e
containing 2 μl cDNA, master mix with SYBR Green
Table 1 Sequences of amplification primers
Gene Primer
LDL
receptor
Sense 5’-CAATGTCTCACCAAGCTCTG-3’
Antisense 5’-TCTGTCTCGAGGGGTAGCTG-3’
HMG-CoA
reductase
Sense 5’-TACCATGTCAGGGGTACGTC-3’
Antisense 5’-CAAGCCTAGAGACATAATCATC
b-actin Sense 5’-AAAGACCTGTACGCCAACACAGTGCTGTCTGG-3’
Antisense 5’-CGTCATACTCCTGCTTGCT GATCCACATCTGC-3’
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Figure 1 EPA effects on HMGCoA reductase (panel a) and LDLR (panel b) mRNA levels in HepG2 cells. All data represent the mean ± SE
of four consecutive experiments. mRNA levels are expressed as ratio of the amount of gene target by the amount of b-actin. P value was
determined by one way analysis with Dunnett’ post test. *P < 0.05 versus control
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sense and antisense primers for HMGCoA reductase,
LDL receptor and b-actin gene (Table 1).
Real-Time PCR was carried out with iCycler Thermal
Cycler System apparatus (Bio-Rad) using the following
parameters: one cycle of 95°C for 1 min and 30 s, fol-
lowed by 45 cycles at 94°C for 10 s, 55°C for 10 s and
72°C for 30 s and a further melting curve step at 55-95°
C with a heating rate of 0.5°C per cycle for 80 cycles.
The PCR products were quantified by external calibra-
tion curves, one for each tested gene, obtained with
serial dilution of known copy number of molecules
(10
2-10
7 molecules). All expression data were normal-
ized by dividing the amount of target by the amount of
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Figure 2 Lovastatin effect on HMGCoA reductase (panel a) and LDLR (panel b) mRNA levels in HepG2 cells. All data represent the mean
± SE of four consecutive experiments. mRNA levels are expressed as ratio of the amount of gene target by the amount of b-actin. P value was
determined by one way analysis with Dunnett’ post test. *P < 0.05 versus control
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specificity of the PCR product of each tested gene was
confirmed by gel electrophoresis.
Assessment of cell proliferation
After Lovastatin and/or EPA treatment for 48 hours, the
proliferative response was estimated by colorimetric 3-
(4,5 di-methylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) test. In brief, MTT stock (5 mg/ml in
medium) was added to each dish at a volume of one-
tenth the original culture volume and incubated for 2
hours at 37°C in humidified CO2. At the end of the
incubation period, the medium was removed, and blue
formazan crystal were solubilized with acidic isopropa-
nol (0.1 N HCl in absolute isopropanol). MTT conver-
sion to formazan by metabolically viable cells was
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Figure 3 HMGCoA reductase (panel a) and LDLR (panel b) mRNA levels after treatment with 50 μMo fE P Aa n di n c r e a s i n g
concentrations of Lovastatin (1, 10, 25, 50 and 100 μM). All data represent the mean ± SE of four consecutive experiments. mRNA levels are
expressed as ratio of the amount of gene target by the amount of b-actin. P value was determined by one way analysis with Dunnett’ post test.
*P < 0.05 versus control.
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570 nm.
Statistical analysis
The significance of the differences between the control
group and each experimental group was evaluated with
one way analysis of variance and the Dunnett’ post test.
Differences were considered significant at a 5% probabil-
ity level.
Results
Results showed that EPA significantly inhibited
HMGCoA reductase gene expression and up-regulated
mRNA LDL receptor (Figure 1a and 1b).
The treatment of HepG2 cells with increasing concen-
trations of Lovastatin caused a similar effect to that
induced by EPA (Figure 2a and 2b). The regulatory
effect on LDLR receptor gene expression was signifi-
cantly evident at higher concentrations (Figure 2b).
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Figure 4 Effect of increasing EPA and Lovastatin concentrations on the conversion of MTT-tetrazolium salt in HepG2 cells and the
combined effect of EPA and Lovastatin on the conversion of MTT-tetrazolium salt in HepG2 cells. Panel a: Effect of increasing EPA and
Lovastatin concentrations on the conversion of MTT-tetrazolium salt in HepG2 cells. A significant anti-proliferative action was observed startinga t
25 μM for both compounds used separately (*P < 0.05 Dunnett’s multiple comparison test). Panel b: combined effect of EPA and Lovastatin on
the conversion of MTT-tetrazolium salt in HepG2 cells (*P < 0.05 Dunnett’s multiple comparison test).
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regulation of expression of both genes were detected at
lower doses (Figure 3a and 3b).
In addition, EPA and Lovastatin, used separately, eli-
cited a significant anti-proliferative effect in HepG2 cells
starting at concentration of 25 μM( F i g u r e4 a ) .T h e
inhibition of cell proliferation was obtained at lower
doses after combined treatment of EPA and Lovastatin
(Figure 4b).
Cell growth inhibitory effect and gene regulation were
similar using fixed EPA or Lovastatin, indifferently.
Discussion
The anti-proliferative activity of EPA and statins has
been suggested by numerous studies showing efficacy in
smooth muscle, glioma, colon, ovarian and hepatoma
cells [16,22-26].
In this study, we demonstrate the efficacy of EPA in
regulation of lipid metabolism, as well as we confirm its
anti-proliferative effects. Analysis of gene expression
revealed in HepG2 cells an inhibition of HMGCoA
reductase mRNA levels accompanied with an up-regula-
tion of LDLR gene expression after EPA treatment.
These effects, on both genes tested, were similar to
those observed after Lovastatin exposure.
The combined treatment with EPA and lovastatin
enhanced the regulatory effect on gene expression of
HMGCoA reductase and LDL receptor in HepG2 cell
line. Moreover, we detected a synergistic effect in the
inhibition of cancer cell proliferation obtained by combi-
nation of EPA and Lovastatin.
The efficacy in regulation of gene expression and cell
proliferation inhibition was detected at the lower doses
with respect to the substances used separately. Further-
more, this synergistic effect of combined treatment was
found to be not cytotoxic.
Previous studies have revealed that PUFA can regulate
the expression of genes involved in several metabolic
pathways [9,27]. Fish oil feeding, rich in the n-3 PUFA,
drastically decreased mRNA levels for lipogenic enzymes
in rodent liver [28]. PUFAs may control cholesterogenic
gene expression through their effects on SREBP- depen-
dent regulation [9]. SREBP-responsive genes include
those coding for HMGCoA reductase and for intermedi-
ates in cholesterol synthesis, as Farnesyl Pirophosphate
Synthase (FPPS). PUFAs decreased mRNA levels of lipo-
genic enzymes in rat hepatoma cells and mouse liver, in
correlation with their effects on HMGCoA reductase [9].
The use of statins as monotherapy in the prevention
or treatment of cancer has been limited in order to
avoid potential detrimental effects that would have a
negative impact on the health and well-being of the
patient.
In order to avoid unwanted adverse side effects asso-
ciated with high doses of statins, several studies have
taken the approach to combine low doses of statins with
other anticancer agents [29,30]. Experimental evidences
suggest that statins and PUFAs have a reciprocal influ-
ence and the combined use of two compounds seems to
have health beneficial effects [1,24].
The present work demonstrates that an additional
advantage of synergistic effect could be the possible
reduction of the doses of statin, thus limiting toxicity.
In conclusion, the pharmacological modulation of
PUFAs combined with low doses of statins, even if mer-
its further investigations in both preclinical and clinical
settings, could be considered favorable in treatment of
neoplastic diseases.
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